GlassScriptPhysician profile
George Mammen
NPI 1588629497
$6,755.56
in general payments reported to CMS, 2019-2025
37 companies · $804 in 2025
The $804 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,794 · 2020: $686 · 2021: $1,059 · 2022: $894 · 2023: $681 · 2024: $837 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,305 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,305.14 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $993.48 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $862.05 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $810.94 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $804.67 | 2019-2023 | Xarelto |
| Boston Scientific Corporation | $379.95 | 2019-2025 | Watchman Flx |
| Edwards Lifesciences Corporation | $368.39 | 2019-2025 | |
| Amarin Pharma, INC. | $301.69 | 2019-2021 | |
| Abbott Laboratories | $282.34 | 2019-2025 | Mitraclip |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $169.18 | 2019-2024 | Lifevest |
| Esperion Therapeutics, INC. | $168.30 | 2020-2023 | Nexletol |
| Impulse Dynamics (USA) INC. | $163.47 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $152.17 | 2019-2023 | Farxiga |
| Pfizer INC. | $143.44 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $139.12 | 2022-2025 | Verquvo |
| Abiomed | $125.00 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.64 | 2019-2023 | Jardiance |
| Abbvie INC. | $103.88 | 2022 | |
| Biotronik INC. | $74.30 | 2019 | |
| Medtronic, INC. | $73.00 | 2022-2024 | Situate |
| Sanofi-Aventis U.S. LLC | $57.62 | 2021-2023 | |
| Chiesi USA, INC. | $53.80 | 2021-2025 | Kengreal |
| Bard Peripheral Vascular, INC. | $45.18 | 2025 | Venclose Maven Catheter |
| Kiniksa Pharmaceuticals International, Plc | $43.32 | 2024 | Arcalyst |
| Bracco Diagnostics INC. | $38.00 | 2021 | |
| Medtronic Vascular, INC. | $36.75 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $29.94 | 2019 | |
| Inspire Medical Systems, INC. | $25.08 | 2023 | Inspire |
| Tactile Systems Technology INC | $23.98 | 2025 | Nimbl, Flexitouch Plus |
| Lexicon Pharmaceuticals, INC. | $23.88 | 2024 | |
| Shockwave Medical, INC | $23.19 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $21.57 | 2023 | Arcalyst |
| Astellas Pharma US INC | $19.99 | 2019 | |
| Novo Nordisk INC | $19.62 | 2025 | Wegovy |
| Scpharmaceuticals INC. | $19.44 | 2023 | |
| Heartflow, INC. | $15.52 | 2024 | |
| Arbor Pharmaceuticals, INC. | $14.08 | 2019 | |
| Cardiva Medical, INC. | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Mammen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.